{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:29:13Z","timestamp":1790306953419,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TR128"],"award-info":[{"award-number":["TR128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GI1603D"],"award-info":[{"award-number":["01GI1603D"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ01FI1603A"],"award-info":[{"award-number":["FKZ01FI1603A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ebiom.2019.07.062","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T07:57:56Z","timestamp":1564387076000},"page":"381-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-8650","authenticated-orcid":false,"given":"Tobias","family":"Ruck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schulte-Mecklenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Windhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2019.07.062_bb0005","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.ebiom.2019.07.062_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ebiom.2019.07.062_bb0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ebiom.2019.07.062_bb0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.ebiom.2019.07.062_bb0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458518804124","article-title":"Sarcoidosis following alemtuzumab treatment: autoimmunity mediated by T cells and interferon-gamma","volume":"24","author":"Pfeuffer","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2019.07.062_bb0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2017.00569","article-title":"Alopecia Universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature","volume":"8","author":"Zimmermann","year":"2017","journal-title":"Front Neurol"},{"issue":"18","key":"10.1016\/j.ebiom.2019.07.062_bb0035","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1212\/WNL.0000000000005420","article-title":"Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab","volume":"90","author":"Saarela","year":"2018","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.ebiom.2019.07.062_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006648","article-title":"Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells","volume":"91","author":"Ruck","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ebiom.2019.07.062_bb0045","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ebiom.2019.07.062_bb0050","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","volume":"85","author":"Azzopardi","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.ebiom.2019.07.062_bb0055","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1089\/thy.2018.0232","article-title":"Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years","volume":"28","author":"Muller","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ebiom.2019.07.062_bb0060","series-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"issue":"1","key":"10.1016\/j.ebiom.2019.07.062_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ebiom.2019.07.062_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/EJE-10-0785","article-title":"Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study","volume":"164","author":"Effraimidis","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.ebiom.2019.07.062_bb0075","doi-asserted-by":"crossref","first-page":"E1466","DOI":"10.1210\/jc.2011-0228","article-title":"Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease","volume":"96","author":"Hutfless","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ebiom.2019.07.062_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000339757","article-title":"The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data","volume":"39","author":"Marrie","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.ebiom.2019.07.062_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2019.07.062_bb0090","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau","year":"2019","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.07.062_bb0095","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/GCO.0000000000000226","article-title":"Thyroid disorders in pregnancy","volume":"27","author":"Yalamanchi","year":"2015","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"10 Supplement","key":"10.1016\/j.ebiom.2019.07.062_bb0100","volume":"82","author":"Twyman","year":"2014","journal-title":"Neurology"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419305043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419305043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:31:17Z","timestamp":1778873477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419305043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":20,"alternative-id":["S2352396419305043"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.062","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}